Dolutegravir Sodium/Lamivudine

多替拉韦钠/拉米夫定

Report date: 2026/05/08 20:02:52

Base Information

Drug NameDolutegravir Sodium/Lamivudine
Drug Alias Name多替拉韦/拉米夫定Lamivudine/Dolutegravir Sodium拉米夫定+多替拉韦钠Lamivudine+Dolutegravir Sodium多替拉韦钠+拉米夫定 +[11] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionHIV integrase inhibitorsReverse transcriptase inhibitors
TargetsHIV integraseReverse transcriptase
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsHIV Infections
Approved Indications in ChinaHIV Infections
Original Approved Country/TerritoryUnited States
Original Approved Date2019/04/08
Country/TerritoryBelgiumCanadaUnited States +[28] 
CombinationsYes LamivudineDolutegravir Sodium
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGlaxosmithkline PlcViiv Healthcare
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline PlcFondazione Policlinico Universitario Agostino Gemelli IrccsGlaxosmithkline Llc +[8] 
Inactive CompaniesN/A
Active IndicationsHIV Infections
Inactive IndicationsN/A

Other Information

ATC CodeJ05AR
Related LinksN/A